US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
pharma · Colitis, Ulcerative · Multiple Myeloma
Janssen Cilag International
Janssen Cilag International NV
Janssen Cilag International drug portfolio — 37 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
São Paulo, EU HQ
13 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- São Paulo, EU
- Employees
- 13
- Programs
- 46
- Drugs
- 37
- Patents
- 0
Janssen Cilag International pipeline
Portfolio lens on 37 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Janssen Cilag International drug portfolio — 37 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
amivantamab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Janssen Cilag International's portfolio. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor inhibitor
-
apalutamide
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
azacitidine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
- Target
- DNA (cytosine-5)-methyltransferase 1
- Mechanism
- DNA (cytosine-5)-methyltransferase 3A inhibitor
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
canagliflozin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.
- Target
- Sodium/glucose cotransporter 2
- Mechanism
- Sodium/glucose cotransporter 2 inhibitor
-
ciltacabtagene autoleucel
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Janssen Cilag International's portfolio. Molecular target: Tumor necrosis factor receptor superfamily member 17.
- Target
- Tumor necrosis factor receptor superfamily member 17
- Mechanism
- Tumor necrosis factor receptor superfamily member 17 binding agent
-
covid-19 vaccine (ad26.cov2-s [recombinant])
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Janssen Cilag International's portfolio. Molecular target: Spike glycoprotein.
- Target
- Spike glycoprotein
- Mechanism
- Spike glycoprotein vaccine antigen
-
daratumumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.
- Target
- ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
- Mechanism
- Lymphocyte differentiation antigen CD38 inhibitor
-
US regulatory status: approved.
-
dengue tetravalent vaccine (live, attenuated)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Janssen Cilag International's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
Development asset linked to Janssen Cilag International in public FDA and regional records.
-
erdafitinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Fibroblast growth factor receptor.
- Target
- Fibroblast growth factor receptor
- Mechanism
- Fibroblast growth factor receptor inhibitor
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
esketamine
Nervous system (N06)Nervous system (N06) compound in Janssen Cilag International's portfolio. Molecular target: Glutamate [NMDA] receptor.
- Target
- Glutamate [NMDA] receptor
- Mechanism
- Glutamate [NMDA] receptor negative allosteric modulator
-
US regulatory status: approved. Molecular target: Sulfonylurea receptor 1, Kir6.2.
- Target
- Sulfonylurea receptor 1, Kir6.2
- Mechanism
- Sulfonylurea receptor 1, Kir6.2 blocker
-
golimumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
guselkumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-23.
- Target
- Interleukin-23
- Mechanism
- Interleukin-23 inhibitor
-
Development asset linked to Janssen Cilag International in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
ibrutinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.
- Target
- Tyrosine-protein kinase BTK
- Mechanism
- Tyrosine-protein kinase BTK inhibitor
-
US regulatory status: approved.
-
influenza vaccine (live attenuated, nasal)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Janssen Cilag International's portfolio.
-
Various (V04) compound in Janssen Cilag International's portfolio.
-
nipocalimab
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in Janssen Cilag International's portfolio. Molecular target: IgG receptor FcRn large subunit p51.
- Target
- IgG receptor FcRn large subunit p51
- Mechanism
- IgG receptor FcRn large subunit p51 antagonist
-
US regulatory status: approved. Molecular target: Ergosterol.
- Target
- Ergosterol
- Mechanism
- Ergosterol sequestering agent
-
olanzapine
Nervous system (N05)US regulatory status: approved. Molecular target: D2-like dopamine receptor.
- Target
- D2-like dopamine receptor
- Mechanism
- D2-like dopamine receptor antagonist
-
paliperidone
Nervous system (N05)US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
Development asset linked to Janssen Cilag International in public FDA and regional records.
-
Development asset linked to Janssen Cilag International in public FDA and regional records.
-
recombinant respiratory syncytial virus pre-fusion f protein, adjuvanted with as01e
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Janssen Cilag International's portfolio. Molecular target: Fusion glycoprotein F0.
- Target
- Fusion glycoprotein F0
- Mechanism
- Fusion glycoprotein F0 vaccine antigen
-
rilpivirine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
-
rituximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
siltuximab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-6.
- Target
- Interleukin-6
- Mechanism
- Interleukin-6 inhibitor
-
US regulatory status: approved. Mechanism: Norepinephrine transporter inhibitor.
- Mechanism
- Norepinephrine transporter inhibitor
-
US regulatory status: approved. Molecular target: Carbonic anhydrase 2.
- Target
- Carbonic anhydrase 2
- Mechanism
- GABA-A receptor; anion channel positive modulator
-
ustekinumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-12.
- Target
- Interleukin-12
- Mechanism
- Interleukin-23 inhibitor